Regulus Therapeutics Inc. Form SC 13G February 14, 2013

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES

13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2

(Amendment No.)*

Regulus Therapeutics Inc.

(Name of Issuer)

COMMON STOCK, \$ 0.001 PAR VALUE

(Title of Class of Securities)


75915K101

(CUSIP Number)

December 31, 2012

 $(Date\ of\ Event\ Which\ Requires\ Filing\ of\ this\ Statement)$

Edgar Filing: Regulus Therapeutics Inc. - Form SC 13G



"Rule 13d-1(c)

x Rule 13d-1(d)

^{*} The remainder of this cover page shall be filled out for a reporting person s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

77-0602661

1. Names of Reporting Persons.

Alnylam Pharmaceuticals, Inc.

I.R.S. Identification Nos. of above persons (entities only).

2.	Check the Appropriate Box if a Member of a Group (See Instructions)		
	(a) "	(t	o)
3.	SEC U	se O	nly
4.	Citizenship or Place of Organization		
	Del		are Sole Voting Power
	mber of	6.	6,150,500 shares Shared Voting Power
Beneficially			
	ned by	7.	0 shares Sole Dispositive Power
P	porting erson With:	8.	6,150,500 shares Shared Dispositive Power
9.	Aggreg	ate 1	0 shares Amount Beneficially Owned by Each Reporting Person
6,150,500 shares 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)			

Edgar Filing: Regulus Therapeutics Inc. - Form SC 13G

11. Percent of Class Represented by Amount in Row (9)

17.2%

12. Type of Reporting Person (See Instructions)

CO

Page 2 of 5 pages

Item 1(a) Name of Issuer:

Regulus Therapeutics Inc.

<u>Item 1(b)</u> <u>Address of Issuer s Principal Executive Offices:</u>

3545 John Hopkins Court

Suite 210

San Diego, California 92121

<u>Item 2(a)</u> Name of Person Filing:

Alnylam Pharmaceuticals, Inc.

<u>Item 2(b)</u> <u>Address of Principal Business Office or, if None, Residence:</u>

300 Third Street

3rd Floor

Cambridge, MA 02142

Item 2(c) Citizenship:

Delaware

<u>Item 2(d)</u> <u>Title of Class of Securities:</u>

Common Stock, \$0.001 par value per share

Item 2(e) CUSIP Number:

75915K101

<u>Item 3</u> <u>Description of Person Filing:</u>

Not applicable

Page 3 of 5 pages

<u>Item 4</u> <u>Ownership:</u>

(a) Amount Beneficially Owned:

6,150,500 shares

(b) Percent of Class:

17.2%

- (c) Number of Shares as to which the Person has:
 - (i) Sole power to vote or direct the vote

6,150,500 shares

(ii) Shared power to vote or to direct the vote

0 shares

(iii) Sole power to dispose or to direct the disposition of

6,150,500 shares

(iv) Shared power to dispose or to direct the disposition of

0 shares

<u>Item 5</u> Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ".

<u>Item 6</u> <u>Ownership of More than Five Percent on Behalf of Another Person:</u>

Not applicable

<u>Item 7</u> <u>Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent</u>

Holding Company or Control Person:

Not applicable

<u>Item 8</u> <u>Identification and Classification of Members of the Group:</u>

Not applicable

<u>Item 9</u> <u>Notice of Dissolution of Group:</u>

Not applicable

Item 10 Certification:

Not applicable

Page 4 of 5 pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I hereby certify that the information set forth in this statement is true, complete and correct.

DATED: February 14, 2013

ALNYLAM PHARMACEUTICALS, INC.

/s/ Michael P. Mason By: Michael P. Mason

Title: Vice President of Finance and Treasurer

Page 5 of 5 pages